The component stock Summit Therapeutics Plc., led the closing with a cumulative increase of 412.68% in the last six months, and rival Merck Pharmaceuticals closed down 1.09%; at 02:32 Beijing time (less than 90 minutes before the closing of the US stock market), the company announced that the Harmoni-2 phase III clinical trial results achieved the main end point, and its effectiveness in controlling specific types of lung cancer surpassed Merck Pharmaceuticals' Keytruda. Humacyte rose 18.03%, Xeris Pharmaceuticals up 15.03%, AC Immune rose 8.17%, and Sarepta Therapeutics also rose 7.05%; Structure Therapeutics ADR closed down 6.79%, showing the penultimate 23Andme Holding Co. falling 8.34%, and Immunovant also falling 10.69%.
成分股Summit Therapeutics Plc.收涨272.06%领跑使得最近六个月累计涨幅达到412.68%其竞争对手默克制药则收跌1.09%；北京时间02:32（距离美股收盘不到90分钟）该公司宣布Harmoni-2第三阶段临床试验结果实现主要终点其控制特定类型肺癌的效果超越默克制药的Keytruda。Humacyte涨18.03%Xeris Pharmaceuticals涨15.03%AC Immune涨8.17%Sarepta...
The component stock Summit Therapeutics Plc., led the closing with a cumulative increase of 412.68% in the last six months, and rival Merck Pharmaceuticals closed down 1.09%; at 02:32 Beijing time (less than 90 minutes before the closing of the US stock m
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.